Treatments against hepatitis C virus have only been partially successful. A major problem is that antivirals generate drug resistance. Now Seong-Wook Lee of Dankook University, Yongin, Republic of ...

Nicola Fletcher, Jane McKeating and colleagues have demonstrated that human brain endothelial cells express all the main receptors required for HCV entry. “This is the first report that cells of the ...

A new compound that inhibits the replication of hepatitis C virus (HCV) in several stages of its lifecycle - and is also capable of acting on bacteria, fungi and cancer cells - has been synthesized by ...

The development of resistance to direct-acting antivirals (DAAs) targeting the hepatitis C virus (HCV) can compromise therapy. However, mechanisms that determine prevalence and frequency of resistance ...

Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

The worldwide outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, has stimulated intensive ...

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected ...

This is a preview. Log in through your library . Abstract Triple antiretroviral therapy combining reverse transcriptase and protease inhibitors modifies the prognosis for human immunodeficiency virus ...

Small Molecule Combination Therapies Are Being Investigated to Increase Response Rates Researchers agree that now is a crucial time to be involved in hepatitis C virus (HCV) research. “Current ...

(A) Immunofluorescence staining of HCV-core protein in HCV replicating Huh7 cells. (B) FACS analysis of EpCAM and CD44 expression in HCV replicating Huh7 cells. (C) RTD-PCR analysis of HCV-RNAin ...

Ruzasvir has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. Ruzasvir has been administered to over 2,100 subjects at daily doses ...